BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 17632543)

  • 1. Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors.
    Lasota J; vel Dobosz AJ; Wasag B; Wozniak A; Kraszewska E; Michej W; Ptaszynski K; Rutkowski P; Sarlomo-Rikala M; Steigen SE; Schneider-Stock R; Stachura J; Chosia M; Ogun G; Ruka W; Siedlecki JA; Miettinen M
    Lab Invest; 2007 Oct; 87(10):1029-41. PubMed ID: 17632543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.
    Søreide K; Sandvik OM; Søreide JA; Gudlaugsson E; Mangseth K; Haugland HK
    Clin Transl Oncol; 2012 Aug; 14(8):619-29. PubMed ID: 22855146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
    Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular characterization of an Italian series of sporadic GISTs.
    Origone P; Gargiulo S; Mastracci L; Ballestrero A; Battistuzzi L; Casella C; Comandini D; Cusano R; Dei Tos AP; Fiocca R; Garuti A; Ghiorzo P; Martinuzzi C; Toffolatti L; ; Bianchi Scarrà G
    Gastric Cancer; 2013 Oct; 16(4):596-601. PubMed ID: 23291969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
    Lasota J; Miettinen M
    Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.
    Lim KH; Huang MJ; Chen LT; Wang TE; Liu CL; Chang CS; Liu MC; Hsieh RK; Tzen CY
    Med Oncol; 2008; 25(2):207-13. PubMed ID: 18488160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
    Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
    Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
    Debiec-Rychter M; Sciot R; Le Cesne A; Schlemmer M; Hohenberger P; van Oosterom AT; Blay JY; Leyvraz S; Stul M; Casali PG; Zalcberg J; Verweij J; Van Glabbeke M; Hagemeijer A; Judson I; ; ;
    Eur J Cancer; 2006 May; 42(8):1093-103. PubMed ID: 16624552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
    Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
    J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pleomorphic phenotypes of gastrointestinal stromal tumors at metastatic sites with or without imatinib treatment.
    Sakamoto K; Sakurai S; Kanda T; Sakuma Y; Hishima T; Hironaka M; Bamba T; Keira Y; Takano Y; Niki T; Hasegawa T; Hirota S
    Cancer Sci; 2010 May; 101(5):1270-8. PubMed ID: 20180814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular domain c-kit mutation with duplication of Ser501Ala502 found in gastrointestinal stromal tumors is more imatinib- and nilotinib-sensitive than that with duplication of Ala502Tyr503.
    Liu NN; Ohkouchi M; Hashikura Y; Kajimoto N; Matsuda I; Isozaki K; Toh Y; Takahashi T; Nishida T; Hirota S
    Lab Invest; 2013 May; 93(5):502-7. PubMed ID: 23459373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
    Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
    Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature.
    Prakash S; Sarran L; Socci N; DeMatteo RP; Eisenstat J; Greco AM; Maki RG; Wexler LH; LaQuaglia MP; Besmer P; Antonescu CR
    J Pediatr Hematol Oncol; 2005 Apr; 27(4):179-87. PubMed ID: 15838387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.
    Yeh CN; Chen TW; Wu TJ; Hsueh S; Jan YY
    World J Gastroenterol; 2006 Jun; 12(23):3760-5. PubMed ID: 16773696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
    Agaram NP; Wong GC; Guo T; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
    Genes Chromosomes Cancer; 2008 Oct; 47(10):853-9. PubMed ID: 18615679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis.
    Zhi X; Zhou X; Wang W; Xu Z
    PLoS One; 2013; 8(11):e79275. PubMed ID: 24223922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular research directions in the management of gastrointestinal stromal tumors.
    Tarn C; Godwin AK
    Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is exon mutation analysis needed for adjuvant treatment of gastrointestinal stromal tumor?
    Sendur MA; Ozdemir NY; Akinci MB; Uncu D; Zengin N; Aksoy S
    World J Gastroenterol; 2013 Jan; 19(1):144-6. PubMed ID: 23326179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in gastrointestinal stromal tumors diagnosed by endoscopic ultrasound-guided fine needle aspiration.
    Schmitt FC; Gomes AL; Milanezi F; Reis R; Bardales RH
    Minerva Med; 2007 Aug; 98(4):385-8. PubMed ID: 17921955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.